With the “bottom-up” method, the mechanistic pyrotinib PBPK model was developed, which was able to capture the absorption and disposition characteristics of pyrotinib in healthy subjects and HER2 positive breast cancer patients at single dose, multiple-dose and DDI scenarios. The gene discussed is ERBB2; the disease is breast cancer.